WHY IT MATTERS: Pregnant individuals using cannabis for nausea, anxiety, or pain should know that emerging placental research suggests potential long-term psychiatric risks to their child that current safety guidelines may still be underestimating. CLINICAL OVERVIEW: Emerging research suggests that prenatal cannabis exposure may leave measurable biological signatures in placental tissue that are associated with increased schizophrenia risk in offspring. The placenta acts as a dynamic interface between maternal and fetal environments, and cannabinoids can cross this barrier and influence fetal neurodevelopment during critical windows of brain formation.
Teen Marijuana Use Doubles Chances of Future Psychotic Disorders, Study Finds
WHY IT MATTERS: Parents and adolescent patients should understand that the psychiatric risks associated with cannabis use before age 18 are biologically distinct from adult-onset use, and delaying initiation until adulthood is one of the most evidence-supported harm reduction strategies available. CLINICAL OVERVIEW: Research examining adolescent cannabis use has consistently identified a meaningful association between early initiation and elevated risk for psychotic spectrum disorders in adulthood, with the biological vulnerability of the developing adolescent brain playing a central role in this relationship. The endocannabinoid system undergoes significant maturation throughout adolescence, and exogenous cannabinoids introduced during this window appear to disrupt neurodevelopmental trajectories in ways that can have lasting psychiatric consequences.